GSK.L
$2026.00
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Intraday
Recent News
GSK's RSV Vaccine Arexvy Wins FDA Nod for High-Risk Younger Adults
GSK secures FDA approval to expand Arexvy's use to high-risk adults aged 18-49 years, broadening access as the company pushes wider global adoption.
GSK BOOSTRIX Settlement Puts Vaccine Messaging And Valuation In Focus
GSK (LSE:GSK) has reached a class action settlement in New York related to advertising claims for its BOOSTRIX vaccine. The case centers on allegations that BOOSTRIX marketing misled consumers about the vaccine's ability to prevent pertussis transmission. The settlement includes financial compensation for eligible claimants and remains subject to court approval. For you as an investor following GSK, this legal development adds a fresh angle to a story that has recently focused more on...
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma
GSK licenses linerixibat to Alfasigma for cholestatic pruritus in PBC, securing $300M upfront and potential milestone payments as the drug awaits FDA review.
JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
J&J gains EU approval to expand Akeega use to treat patients with BRCA-mutated metastatic hormone-sensitive prostate cancer.
GSK Reworks Liver Portfolio As Linerixibat Deal Raises Valuation Questions
GSK (LSE:GSK) has licensed worldwide rights to its experimental liver disease drug linerixibat to Alfasigma. The agreement covers development and commercialization of linerixibat as GSK reallocates resources within its liver pipeline. The deal includes an upfront payment to GSK, along with potential future milestones and royalties tied to linerixibat. For you as an investor, this move reflects how GSK is reshaping its late stage R&D mix and choosing where to commit capital. The company is...